Aura Biosciences (AURA) to Release Quarterly Earnings on Tuesday

Aura Biosciences (NASDAQ:AURA) is expected to be issuing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 11, 2025 at 9:30 AM ET.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. On average, analysts expect Aura Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Aura Biosciences Price Performance

Shares of AURA stock opened at $5.35 on Friday. Aura Biosciences has a 12-month low of $4.34 and a 12-month high of $11.22. The firm has a market capitalization of $332.34 million, a price-to-earnings ratio of -2.73 and a beta of 0.45. The business has a 50 day simple moving average of $6.09 and a 200 day simple moving average of $6.23.

Insider Activity

In related news, insider Los Pinos Elisabet De sold 9,049 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $6.35, for a total value of $57,461.15. Following the transaction, the insider directly owned 474,391 shares of the company’s stock, valued at approximately $3,012,382.85. This trade represents a 1.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Amy Elazzouzi sold 7,722 shares of Aura Biosciences stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $6.70, for a total value of $51,737.40. Following the completion of the transaction, the senior vice president directly owned 86,558 shares in the company, valued at approximately $579,938.60. This represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 29,836 shares of company stock valued at $192,161. Insiders own 6.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its stake in shares of Aura Biosciences by 49.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after purchasing an additional 2,104 shares in the last quarter. Invesco Ltd. acquired a new position in Aura Biosciences in the second quarter valued at about $76,000. BNP Paribas Financial Markets grew its stake in Aura Biosciences by 286.6% during the second quarter. BNP Paribas Financial Markets now owns 13,499 shares of the company’s stock worth $85,000 after buying an additional 10,007 shares during the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Aura Biosciences during the second quarter worth approximately $102,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aura Biosciences during the first quarter worth approximately $137,000. Institutional investors own 96.75% of the company’s stock.

Wall Street Analyst Weigh In

AURA has been the topic of a number of research analyst reports. Zacks Research raised Aura Biosciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a research note on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.50.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.